Horn Margaret A's Form 4 filing
Revolution Medicines, Inc. (RVMD) · filed Jun 17, 2026
- Accession no.
- 0001610717-26-000230
- Filed
- Jun 17, 2026
- Trade date
- Jun 16, 2025-Jun 17, 2026
- Filing delay
- 366 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 5 derivative transactions. Open-market sales total $15.0M. It was filed 366 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Horn Margaret ACIK 0001294192 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseAcquired | +15,546 | $40.74 | +$633,344.04 | 173,768 | Direct | |
| Jun 15, 2026 | Common Stock | MOption exerciseAcquired | +44,854 | $29.80 | +$1,336,649.2 | 218,622 | Direct | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −60,400 | $160.17F3 | −$9,674,268 | 158,222 | Direct | |
| Jun 16, 2025 | Common Stock | SSaleDisposed | −3,575 | $156.12F5 | −$558,129 | 154,647 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseAcquired | +573 | $40.74 | +$23,344.02 | 155,220 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseAcquired | +3,302 | $29.80 | +$98,399.6 | 158,522 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseAcquired | +25,725 | $26.50 | +$681,712.5 | 184,247 | Direct | |
| Jun 17, 2026 | Common Stock | SSaleDisposed | −29,600 | $160.12F7 | −$4,739,552 | 154,647 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseDisposed | −15,546 | $0.00 | $0 | 75,648 | Direct | |
| Jun 15, 2026 | Common Stock | MOption exerciseDisposed | −44,854 | $0.00 | $0 | 75,052 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseDisposed | −573 | $0.00 | $0 | 75,075 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseDisposed | −3,302 | $0.00 | $0 | 71,750 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseDisposed | −25,725 | $0.00 | $0 | 114,275 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades in prices ranging from $160.00 to $160.3550, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades in prices ranging from $156.1105 to $156.8250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades in prices ranging from $160.00 to $160.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.